Vera Therapeutics Secures FDA Accelerated Approval for TRUTAKNA in IgA Nephropathy — Vera Therapeutics, Inc.

Event summary

Vera Therapeutics' TRUTAKNA received FDA accelerated approval for reducing proteinuria in adults with primary IgA nephropathy (IgAN).
The approval is based on a 46% reduction in proteinuria from baseline, compared to a 42% reduction versus placebo at 36 weeks.
TRUTAKNA is the first and only therapy targeting both BAFF and APRIL, key cytokines involved in IgAN pathophysiology.
Continued approval contingent upon verification of clinical benefit in the ongoing ORIGIN 3 trial, with results expected in Q3 2026.

The big picture

Vera Therapeutics' FDA approval marks a significant milestone in the treatment of IgA nephropathy, a progressive kidney disease with limited therapeutic options. The accelerated approval underscores the urgent need for effective treatments and positions Vera to capture a substantial share of the IgAN market. The strategic focus on targeting BAFF and APRIL cytokines differentiates TRUTAKNA from existing therapies, potentially setting a new standard in autoimmune kidney disease management.

What we're watching

Clinical Validation: Whether TRUTAKNA can demonstrate long-term kidney function benefits in the ongoing ORIGIN 3 trial.
Market Penetration: The pace at which Vera Therapeutics can commercialize TRUTAKNA given the significant unmet need in IgAN.
Competitive Landscape: How TRUTAKNA's unique mechanism of action will position it against emerging therapies for IgAN.